Expect a sector-wide lift after Canopy Growth Mettrum deal, says M Partners

The acquisition of Mettrum Health (Mettrum Health Stock Quote, Chart, News: TSXV:MT) by Canopy Growth Corp. (Canopy Growth Corp. Stock Quote, Chart, News: TSX:CGC) shows there may yet be another level to the already stratospheric rise of Canada’s marijuana sector, says M Partners analyst mason Brown.

Late Wednesday, Canopy announced it would acquire peer Mettrum in a deal valued at approximately C$430 million.

“From day one, Canopy Growth has viewed production capacity, brand diversity, and highly-skilled management as the foundational aspects of our business,” said Canopy CEO Bruce Linton. “Mettrum has established a line of cannabis products that work well in a medical context and will transition naturally into a natural and healthy lifestyle market. Their substantial production facilities will add to our growing production platform as we expand to meet the needs of patients, and their experienced personnel will help Canopy Growth drive our vision forward to the next level. Both Canopy Growth and Mettrum have proven themselves with Canadian patients; and together we intend to make our industry-leading product and service offering even stronger, while developing our common hemp objectives.”

Brown says the acquisition is a signal that the party in Canada’s marijuana sector might not be over yet.

“We expect a lift across the sector as Canopy displays that there is still long-term value within the sector despite the run-up in prices over the past few months,” says Brown. “…we highlight how we look at the industry from a long-term perspective and believe that there is still material upside for all players in the space.”

Brown say the deal scales Canopy considerably, giving the LP a more than 40% market share of patients on a pro forma basis.

“The acquisition expands Canopy’s portfolio of cannabis and hemp brands, is expected to realize revenue and cost synergies, and adds ~$27mm in net cash to Canopy’s balance sheet, leaving the company well-funded for expansion on a local and global scale,” says the analyst. “Recall, Canopy Growth acquired a majority ownership position in Groupe Hemp. Integrating Mettrum Originals is expected to solidify Canopy’s position in the hemp market, a valuable play as the hemp market provides marketing and advertising opportunities by getting on the shelves of grocery stores and furthering brand recognition. Canopy expects revenue and cost synergies to occur via cross-selling to customers, given a broader product offering, and improved supply chain management. Before exercise of options and warrants, the acquisition brings Canopy’s cash balance to ~$68mm and positions the company to continue its expansion plans.”

In a research update to clients today, Brown placed his rating and target on Canopy Growth Corp. under review.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cgcmt
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

14 hours ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

24 hours ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

1 day ago

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

2 days ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

2 days ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

2 days ago